LenioBio GmbH is a contract research and development organization dedicated to transforming protein production through its proprietary ALiCE® technology; the only eukaryotic cell-free system that scales reliably and seamlessly from early research to large-scale production. ALiCE® -
offers a breakthrough solution, streamlining the antigen production process with unparalleled efficiency
has a strong track-record expressing proteins with a broad range of complexity
includes antigens that have proven resistant to expression in cell-based systems
From rapid antigen screening to antigen characterization, with ALiCE®, the journey from pathogen discovery to vaccine deployment becomes streamlined, efficient, and effective.